Health ❯ Healthcare ❯ Medicine

Oncology

Prostate Cancer Lung Cancer Chronic Lymphocytic Leukemia Breast Cancer Lymphoma Glioblastoma Acute Myeloid Leukemia Clinical Trials Pancreatic Cancer Multiple Myeloma Immunotherapy Cancer Research Chemotherapy Leukemia Biomarkers Personalized Medicine Mastocytosis Targeted Therapy Nasopharyngeal Carcinoma Brain Tumors Gastroesophageal Cancer Hepatocellular Carcinoma Neuro-oncology Meningioma Research Findings Radiation Therapy Hematology Colorectal Cancer Cancer Biology Drug Combinations Non-Small Cell Lung Cancer Antibody-Drug Conjugates Cancer Treatment Progression-Free Survival

3 ARTICLES

2mo ago

WashU Team Uses In‑Body Click Chemistry to Assemble Dual‑Target Cancer Drugs

Mouse tests show higher tumor drug buildup with restored activity, prompting preclinical optimization of safety and dosing for possible clinical testing.

3 ARTICLES

2mo ago

TROP2 Pinpoints and Permits Targeted Attack on Metastasis‑Driving Colorectal Cells

5 ARTICLES

3mo ago

Erleada Plus Hormone Therapy Cuts Recurrence and Death in High‑Risk Localized Prostate Cancer

3 ARTICLES

4mo ago

FDA Clears All-Oral Decitabine/Cedazuridine Plus Venetoclax for Older AML Patients

3 ARTICLES

4mo ago

Testosterone Loss Linked to Faster Glioblastoma Growth in Men

13 ARTICLES

4mo ago

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

5 ARTICLES

5mo ago

Revolution Medicines’ Pancreatic Cancer Drug Lands ASCO Plenary After Phase 3 Survival Gain

6 ARTICLES

5mo ago

Metformin Triggers Exercise-Linked Signal in Prostate Cancer Patients

3 ARTICLES

6mo ago

Pfizer’s Talzenna Plus Xtandi Delivers Phase 3 Win in Hormone-Sensitive Prostate Cancer

3 ARTICLES

7mo ago

Oncolytic Viruses Trigger T‑Cell Infiltration and Survival Signals in Early Glioblastoma Trials

4 ARTICLES

8mo ago

Tecvayli Cuts Progression Risk 71% and Deaths 40% in Phase 3 Myeloma Trial

7 ARTICLES

9mo ago

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

11 ARTICLES

9mo ago

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

5 ARTICLES

9mo ago

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

3 ARTICLES

9mo ago

Silevertinib Delivers 60% Response and Strong CNS Activity in First-Line NSCLC With Non-Classical EGFR Mutations

5 ARTICLES

11mo ago

ASCENT-03 Finds Sacituzumab Govitecan Extends PFS Over Chemotherapy in First-Line PD-L1–Negative TNBC

6 ARTICLES

11mo ago

Roche’s Giredestrant Plus Everolimus Extends PFS in Phase 3 evERA for ER-Positive, HER2-Negative Breast Cancer

Oncology

WashU Team Uses In‑Body Click Chemistry to Assemble Dual‑Target Cancer Drugs

TROP2 Pinpoints and Permits Targeted Attack on Metastasis‑Driving Colorectal Cells

Erleada Plus Hormone Therapy Cuts Recurrence and Death in High‑Risk Localized Prostate Cancer

FDA Clears All-Oral Decitabine/Cedazuridine Plus Venetoclax for Older AML Patients

Testosterone Loss Linked to Faster Glioblastoma Growth in Men

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

Revolution Medicines’ Pancreatic Cancer Drug Lands ASCO Plenary After Phase 3 Survival Gain

Metformin Triggers Exercise-Linked Signal in Prostate Cancer Patients

Pfizer’s Talzenna Plus Xtandi Delivers Phase 3 Win in Hormone-Sensitive Prostate Cancer

Oncolytic Viruses Trigger T‑Cell Infiltration and Survival Signals in Early Glioblastoma Trials

Never miss stories about

Oncology

Tecvayli Cuts Progression Risk 71% and Deaths 40% in Phase 3 Myeloma Trial

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

Silevertinib Delivers 60% Response and Strong CNS Activity in First-Line NSCLC With Non-Classical EGFR Mutations

ASCENT-03 Finds Sacituzumab Govitecan Extends PFS Over Chemotherapy in First-Line PD-L1–Negative TNBC

Roche’s Giredestrant Plus Everolimus Extends PFS in Phase 3 evERA for ER-Positive, HER2-Negative Breast Cancer

Never miss stories about

Oncology